Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115471) titled 'Disitamab Vedotin combining with Toripalimab versus adjuvant Toripalimab in HER2 expressed locally advanced UTUC patients after nephron-ureterectory: a prospective, multicentre, open-label, randomised, phase 3 trial' on Dec. 26, 2025.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Sun Yat-sen University Cancer Center
Condition:
Upper tract urothelial carcinoma
Intervention:
Trial group:Toripalimab (240 mg, every 3 weeks, for 1 year) + Disitamab vedotin (2.0 mg/kg, every 3 weeks, for 8 cycles)
Recruitment Status: Not Recruiting
Phase: 3
Date of First Enrollment: 2025-12-31
T...